Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX
· Real-Time Price · USD
0.86
-0.00 (-0.29%)
At close: May 02, 2025, 12:28 PM
-0.29% (1D)
| Bid | 0.86 |
| Market Cap | 77.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.73M |
| EPS (ttm) | -0.46 |
| PE Ratio (ttm) | -1.87 |
| Forward PE | -2.55 |
| Analyst | Buy |
| Ask | 0.87 |
| Volume | 17,933 |
| Avg. Volume (20D) | 154,566 |
| Open | 0.89 |
| Previous Close | 0.86 |
| Day's Range | 0.84 - 0.89 |
| 52-Week Range | 0.55 - 2.75 |
| Beta | 2.18 |
About CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also dev...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2021
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CNTX
Analyst Forecast
According to 6 analyst ratings, the average rating for CNTX stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 481.33% from the latest price.
Stock Forecasts
